Op-Eds

FDA must decide if a biosimilar rose by any other name is still a rose

By Peter Pitts
Published December 9, 2013 5:00am ET
Add Washington Examiner on Google
FDA must decide if a biosimilar rose by any other name is still a rose
When it comes to biosimilars, we need to be extremely thoughtful about how we set policy relating to these promising medicines and strike a balance that promotes health and safety, rather than forcing a binary response that is driven by profits rather than patients. (Photo: Thinkstock) | badmanproduction

“A good name is better than precious ointment.” – Ecclesiastes 7:1

Federal approval of biosimilars promises to be a very good thing, but the devil is in the details. Unfortunately, we’re seeing a disturbing trend relating to one of those key details: naming nomenclature.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

FDA Health Pharmaceutical Industry